YURAK ISHEMIK KASALLIGIDA TURLI KONSENTRATSIYADAGI AGREGATSIYA INDUKTORLARI TA’SIRIDA ANTIAGREGANT REZISTENTLIKNI BAHOLASH
##article.subject##:
antiagregantga rezistentlik, trombotsitlar agregatsiyasi, yurak ishemik kasalligi##article.abstract##
Yurak ishemik kasalligi bilan hasta bo‘lgan 130 bemorda muntazam antiagregant terapiya fonida trombotsitlar agregatsiyasi tekshiruvi natijalari tahlil qilindi va ular asosida antiagregantga rezistentlik holatini tashxislash amalga oshirildi. O‘tkazilgan tadqiqotlar muntazam antiagregant davoga qaramasdan yurak ishemik kasalligi bor bemorlarning deyarli 1/4 qismida trombotsitlar agregatsiyasi yetarli darajada ingibirlanmasligi va preparatga nisbatan rezistentlik holati rivojlanishi aniqlandi. Asosan spontan agregatsiya va induktorning yuqori konsentratsiyasi ta’sir qilgan trombotsitlar agregatsiyasi o‘zgarishlari ko‘proq kuzatildi
Библиографические ссылки
Atherosclerosis and dyslipidemia. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian Recommendations, VII revision. 2020;1(38):7-42. (in Russ).
Khodzhanova S.I., Alavi A.L. (2025). Resistance to antiplatelet therapy: Mechanisms, types, causes, diagnosis. Medical Journal of Young Scientists, 1(13 (03), 117–126.(in Russ).
Anis A., Shakhnoza K., Shoira K. Role of the acetylsalicylic acid in the treatment of coronary artery disease //Biomedical Research. – 2020. – Т. 31. – №. 4. – С. 82-85.
Alyavi A. L. et al. Aspirin resistance in patients with chronic coronary syndrome //Indian Journal of Forensic Medicine & Toxicology. – 2021. – Т. 15. – №. 3. – С. 1843-1846.
Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease. (2022). Journal of Pharmaceutical Negative Results, 754-760.
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32: 2999–3054.
Geisler T., Zurn Ch., Simonenko R. et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions // Eur Heart J.- 2010.-Vol. 31.-P. 59–66.
Grinshtein Y.I., Savchenko A.A., Kosinova A.A. et al. Resistance to acetylsalicylic acid in patients with coronary heart disease is the result of metabolic activity of platelets. Pharmaceuticals. 2020;13(8):178.
Juhani Knuuti., William Wijns, Antti Saraste and al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)// European Heart Journal.-2020 -Vol.41(3).-P. 407–477.
Serkan Kahraman, Ali Dogan, Murat Ziyrek, et al. The association between aspirin resistance and extent and severity of coronary atherosclerosis. // North Clin Istanb.- 2018-Vol. 5(4).-P. 323–328.
